345 related articles for article (PubMed ID: 29589203)
1. Anabolic Therapy for the Treatment of Osteoporosis in Childhood.
Ward LM; Rauch F
Curr Osteoporos Rep; 2018 Jun; 16(3):269-276. PubMed ID: 29589203
[TBL] [Abstract][Full Text] [Related]
2. Anabolic agents: what is beyond osteoporosis?
Liu Y; Levack AE; Marty E; Or O; Samuels BP; Redko M; Lane JM
Osteoporos Int; 2018 May; 29(5):1009-1022. PubMed ID: 29627891
[TBL] [Abstract][Full Text] [Related]
3. The future of osteoporosis treatment - a research update.
Lippuner K
Swiss Med Wkly; 2012; 142():w13624. PubMed ID: 22815185
[TBL] [Abstract][Full Text] [Related]
4. Abaloparatide: Recombinant human PTHrP (1-34) anabolic therapy for osteoporosis.
Chew CK; Clarke BL
Maturitas; 2017 Mar; 97():53-60. PubMed ID: 28159062
[TBL] [Abstract][Full Text] [Related]
5. Targeted inhibition of sclerostin for post-menopausal osteoporosis therapy: A critical assessment of the mechanism of action.
Bhattacharyya S; Pal S; Chattopadhyay N
Eur J Pharmacol; 2018 May; 826():39-47. PubMed ID: 29476877
[TBL] [Abstract][Full Text] [Related]
6. [Update and perspectives of anabolic therapies for osteoporosis].
Endo I; Matsumoto T
Clin Calcium; 2012 Mar; 22(3):327-33. PubMed ID: 22370299
[TBL] [Abstract][Full Text] [Related]
7. Parathyroid hormone as an anabolic skeletal therapy.
Rubin MR; Bilezikian JP
Drugs; 2005; 65(17):2481-98. PubMed ID: 16296873
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of anabolic therapies for osteoporosis.
Canalis E; Giustina A; Bilezikian JP
N Engl J Med; 2007 Aug; 357(9):905-16. PubMed ID: 17761594
[No Abstract] [Full Text] [Related]
9. Management of postmenopausal osteoporosis and the prevention of fractures.
Gambacciani M; Levancini M
Panminerva Med; 2014 Jun; 56(2):115-31. PubMed ID: 24942322
[TBL] [Abstract][Full Text] [Related]
10. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.
Brixen KT; Christensen PM; Ejersted C; Langdahl BL
Basic Clin Pharmacol Toxicol; 2004 Jun; 94(6):260-70. PubMed ID: 15228497
[TBL] [Abstract][Full Text] [Related]
11. Combination/sequential therapies for anabolic and antiresorptive skeletal agents for osteoporosis.
Bilezikian JP; Rubin MR
Curr Osteoporos Rep; 2006 Mar; 4(1):5-13. PubMed ID: 16527002
[TBL] [Abstract][Full Text] [Related]
12. The use of parathyroid hormone in the treatment of osteoporosis.
Girotra M; Rubin MR; Bilezikian JP
Rev Endocr Metab Disord; 2006 Jun; 7(1-2):113-21. PubMed ID: 17043762
[TBL] [Abstract][Full Text] [Related]
13. MANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis.
Canalis E
Eur J Endocrinol; 2018 Feb; 178(2):R33-R44. PubMed ID: 29113980
[TBL] [Abstract][Full Text] [Related]
14. Biological agents in management of osteoporosis.
Tella SH; Gallagher JC
Eur J Clin Pharmacol; 2014 Nov; 70(11):1291-301. PubMed ID: 25204309
[TBL] [Abstract][Full Text] [Related]
15. New anabolic therapies for osteoporosis.
Minisola S; Cipriani C; Occhiuto M; Pepe J
Intern Emerg Med; 2017 Oct; 12(7):915-921. PubMed ID: 28780668
[TBL] [Abstract][Full Text] [Related]
16. Anabolic therapies for osteoporosis.
Uihlein AV; Leder BZ
Endocrinol Metab Clin North Am; 2012 Sep; 41(3):507-25. PubMed ID: 22877427
[TBL] [Abstract][Full Text] [Related]
17. New therapeutic targets for osteoporosis: beyond denosumab.
Lim V; Clarke BL
Maturitas; 2012 Nov; 73(3):269-72. PubMed ID: 22925430
[TBL] [Abstract][Full Text] [Related]
18. New understanding and treatments for osteoporosis.
Mazziotti G; Bilezikian J; Canalis E; Cocchi D; Giustina A
Endocrine; 2012 Feb; 41(1):58-69. PubMed ID: 22180055
[TBL] [Abstract][Full Text] [Related]
19. Anabolic Strategies to Augment Bone Fracture Healing.
Roberts SJ; Ke HZ
Curr Osteoporos Rep; 2018 Jun; 16(3):289-298. PubMed ID: 29725836
[TBL] [Abstract][Full Text] [Related]
20. Anabolic bone therapies in 2014: New bone-forming treatments for osteoporosis.
Papapoulos SE
Nat Rev Endocrinol; 2015 Feb; 11(2):69-70. PubMed ID: 25488486
[No Abstract] [Full Text] [Related]
[Next] [New Search]
